Kartosthera
Founded 2018 · 70 employees on LinkedIn · 2 known investors
Kartos Therapeutics develops targeted oral therapeutics for cancer, including Navtemadlin, an MDM2 inhibitor aimed at the MDM2-p53 interaction to treat selected solid tumors and hematological malignancies. The company focuses on novel small-molecule drugs for oncology patients.
Investors · 2
Frequently asked questions
- What does Kartosthera do?
- Kartos Therapeutics develops targeted oral therapeutics for cancer, including Navtemadlin, an MDM2 inhibitor aimed at the MDM2-p53 interaction to treat selected solid tumors and hematological malignancies. The company focuses on novel small-molecule drugs for oncology patients.
- Who are Kartosthera's investors?
- Kartosthera's investors include OrbiMed, SR One Capital Management.